1. Supplemental Figure 1. Erlotinib does not alter oxygenation of tumors. Tumor pO 2 was measured by phosphorescence lifetime oximetry at times before erlotinib administration (0h), then at 24h, 48h, and 51h post-erlotinib administration. These timepoints were evaluated because they follow the dosing schedule used for the combination erlotinib/PDT regimen under investigation. Plots represent individual animals. No significant alterations in pO 2 levels were observed at any timepoint post-erlotinib administration.

2. # Ctrl PDT Ctrl * * * Supplemental Figure 2. Erlotinib increases in vivo tumor cell death at delayed timepoints. In vivo H460 viability, and the presence of necrosis and apoptosis, assessed by flow cytometry (n=4-6). *p<0.05 compared to untreated, #p<0.05 for erlotinib/PDT vs. PDT.

3. Ctrl PDT Ctrl Ex vivo imaging (FI/unit area) In vivo imaging (FI/unit area) r=0.99 Supplemental Figure 3. In vivo imaging of tumor perfusion is well correlated with ex vivo imaging of the excised tumor. In H460 tumors, in vivo imaging of IRDye®800-PEG uptake was compared to images of the same tumors that were taken after their excision. Data are plotted as the average fluorescence (FI) per unit area of the region of interest (ROI). ROI was customized to the dimensions of the tumor for both the in vivo and the ex vivo images.

4. Ctrl PDT Ctrl Supplemental Figure 4. VEGF levels decrease in A549 tumors with pre-PDT administration of erlotinib. Relative concentrations of tumor-localized human VEGF (hVEGF) in A549 tumors at 18h after treatment with PDT compared to treatment with erlotinib/PDT (n=6). BPD-PDT

5. Ctrl PDT Ctrl Blot: EGFR Actin SVEC A549 H460 Supplemental Figure 5. Western blot analysis shows that EGFR is expressed in each of the cell lines studied. β-actin serves as the internal loading control. SVEC, mouse endothelial cell line; H460/A549, human non-small cell lung carcinoma cell lines.

6. Ctrl PDT Ctrl Supplemental Figure 6. BPD levels increase in A549 tumors after Erlotinib administration. In vivo imaging of BPD uptake after triple-dose erlotinib regimen compared to untreated (n=4).

7. Ctrl PDT ControlsBPD-PDT * * # Supplemental Figure 7. A single-dose of erlotinib augments PDT-induced cytotoxicity. Control conditions indicate the surviving fraction of SVEC endothelial cells that were unilluminated and untreated with erlotinib, or unilluminated and exposed to erlotinib. In parallel, cells that were or were not exposed to erlotinib were treated with 0.8 J/cm 2 of BPD-PDT. Surviving fractions are calculated relative to untreated controls (no illumination or erlotinib). Erlotinib incubation was over the 3 hours prior to PDT (simultaneous with incubation in BPD). By paired t-test, *p<0.05 compared to untreated, #p<0.05 for erlotinib/PDT vs. PDT.